Mark P Chao

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA, USA
    Blood 118:4890-901. 2011
  2. pmc The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine and Cancer Institute, Stanford, CA 94305, USA
    Curr Opin Immunol 24:225-32. 2012
  3. doi request reprint Programmed cell removal: a new obstacle in the road to developing cancer
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine and Cancer Institute, Division of Haematology, Stanford University School of Medicine, Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, California 94305, USA
    Nat Rev Cancer 12:58-67. 2012
  4. pmc Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
  5. pmc Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Palo Alto, California, USA
    Cancer Res 71:1374-84. 2011
  6. doi request reprint Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
  7. pmc CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell 138:286-99. 2009
  8. pmc Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
    Max Jan
    Program in Cancer Biology, Cancer Center, Institute for Stem Cell Biology and Regenerative Medicine, Department of Internal Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA
    Proc Natl Acad Sci U S A 108:5009-14. 2011
  9. pmc The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
    Stephen B Willingham
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 109:6662-7. 2012
  10. pmc Macrophages as mediators of tumor immunosurveillance
    Siddhartha Jaiswal
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, USA
    Trends Immunol 31:212-9. 2010

Collaborators

Detail Information

Publications13

  1. pmc Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA, USA
    Blood 118:4890-901. 2011
    ..Ultimately, these findings are potentially applicable to the dissemination and metastasis of other solid tumors...
  2. pmc The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine and Cancer Institute, Stanford, CA 94305, USA
    Curr Opin Immunol 24:225-32. 2012
    ....
  3. doi request reprint Programmed cell removal: a new obstacle in the road to developing cancer
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine and Cancer Institute, Division of Haematology, Stanford University School of Medicine, Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, California 94305, USA
    Nat Rev Cancer 12:58-67. 2012
    ..In this Opinion article, we explore the role of programmed cell removal in both normal and neoplastic cells, and we place this pathway in the context of the initiation of programmed cell death...
  4. pmc Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
    ..These antibodies synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers...
  5. pmc Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Palo Alto, California, USA
    Cancer Res 71:1374-84. 2011
    ..These data provide preclinical support for the development of an anti-CD47 antibody therapy for treatment of human ALL...
  6. doi request reprint Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
    ....
  7. pmc CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell 138:286-99. 2009
    ..In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC...
  8. pmc Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
    Max Jan
    Program in Cancer Biology, Cancer Center, Institute for Stem Cell Biology and Regenerative Medicine, Department of Internal Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA
    Proc Natl Acad Sci U S A 108:5009-14. 2011
    ..Significantly, differential TIM3 expression enabled the prospective separation of HSC from LSC in the majority of AML specimens with detectable residual HSC function...
  9. pmc The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
    Stephen B Willingham
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 109:6662-7. 2012
    ..CD47 is therefore a validated target for cancer therapies...
  10. pmc Macrophages as mediators of tumor immunosurveillance
    Siddhartha Jaiswal
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, USA
    Trends Immunol 31:212-9. 2010
    ..These results implicate macrophages in the immunosurveillance of hematopoietic cells and leukemias. The ability of macrophages to phagocytose tumor cells might be exploited therapeutically by blocking the CD47-SIRPalpha interaction...
  11. pmc CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009
    ..We conclude that CD47 upregulation is an important mechanism that provides protection to normal HSCs during inflammation-mediated mobilization, and that leukemic progenitors co-opt this ability in order to evade macrophage killing...
  12. pmc CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
    Holbrook E Kohrt
    Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
    Blood 117:2423-32. 2011
    ..These results support a novel, sequential antibody approach against B-cell malignancies by targeting first the tumor and then the host immune system...